Table 1.
Patient characteristics of the evaluation cohorts for TF TAVR, iSAVR, and SAVR+CABG (2015-2019)
| Characteristic | TF TAVR (N = 2070) | iSAVR (N = 1774) | SAVR+CABG (N = 1429) |
|---|---|---|---|
| Age, y | 81.4 ± 7.6 | 68.1 ± 10.3 | 72.5 ± 7.7 |
| Age ≥ 80 y | 1397 (67.5) | 878 (49.5) | 963 (67.4) |
| Female sex | 897 (43.3) | 643 (36.2) | 267 (18.7) |
| Body mass index, kg/ m2 | 28.1 ± 6.3 | 27.6 ± 5.7 | 28.2 ± 5.2 |
| Body surface area, m2 | 1.9 ± 0.3 | 2.0 ± 0.3 | 2.0 ± 0.2 |
| Atrial fibrillation/flutter | 679 (33.7) | 181 (10.2) | 157 (11) |
| LVEF < 35% | 195 (9.4) | 96 (5.4) | 101 (7.1) |
| NYHA functional class III or IV | 1180 (62.5) | 707 (39.9) | 548 (38.3) |
| Congestive heart failure | N/A | 589 (33.2) | 493 (34.5) |
| eGFR, mL/min | 58.6 ± 19.8 | 75.7 ± 47.5 | 70.6 ± 21.6 |
| Dialysis | 42 (2.1) | 22 (1.2) | 25 (1.7) |
| COPD | N/A | 340 (19.2) | 294 (20.6) |
| Diabetes | 580 (28.6) | 413 (23.3) | 560 (39.2) |
| Liver disease | N/A | 128 (7.2) | 90 (6.3) |
| Pulmonary hypertension | N/A | 1177 (66.3) | 1175 (82.2) |
| PCI | 517 (25.5) | 92 (5.2) | 234 (16.4) |
| CABG | 322 (15.9) | 45 (2.5) | 39 (2.7) |
| Prior AVR | 193 (9.3) | 101 (5.7) | 32 (2.2) |
| PVD | N/A | 113 (6.4) | 210 (14.7) |
| Pacemaker | 147 (11.1) | 53 (3) | 43 (3) |
| Preoperative ventilation | N/A | 9 (0.5) | 7 (0.5) |
| AV gradient | 42.3 ± 15.8 | 49.1 ± 25.9 | 41.2 ± 17 |
| AV area | 0.8 ± 1.4 | 0.8 ± 1.4 | 1 ± 3.3 |
| Moderate or severe anemia∗ | 106 (7.5) | 129 (7.3) | 129 (9) |
| Malignant disease < 5 y | N/A | 172 (9.7) | 165 (11.5) |
| History of substance use disorder | N/A | 43 (2.4) | 18 (1.3) |
| Depression | N/A | 103 (5.8) | 39 (2.7) |
| KCCQ-OS | 47.5 ± 24.6 | N/A | N/A |
| Elective outpatient | 1730 (84) | N/A | N/A |
| Priority II or III∗ | N/A | 1636 (92.3) | 1273 (89.1) |
Values are n (%) or mean (± standard deviation), unless otherwise indicated.
AV, atrioventricular; AVR, AV replacement; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; iSAVR isolated SAVR; KCCQ-OS, Kansas City Cardiomyopathy Questionnaire overall score; LVEF, left ventricular ejection fraction; N/A, not available (variable not routinely collected for procedure); NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement; TF, transfemoral.
Derived variables: SAVR priority level II: elective outpatient wait time < 6 weeks; SAVR priority level III: elective outpatient wait time < 12 weeks; moderate or severe anemia: hemoglobin < 110 g/L.